WO2025237891 - QUINOLINE-2-CARBOXAMIDE DERIVATIVES AS RAD51 INHIBITORS FOR THE TREATMENT OF CANCER
National phase entry is expected:
Publication Number
WO/2025/237891
Publication Date
20.11.2025
International Application No.
PCT/EP2025/062878
International Filing Date
12.05.2025
Title **
[English]
QUINOLINE-2-CARBOXAMIDE DERIVATIVES AS RAD51 INHIBITORS FOR THE TREATMENT OF CANCER
[French]
DÉRIVÉS DE QUINOLÉINE-2-CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS DE RAD51 POUR LE TRAITEMENT DU CANCER
Applicants **
NERVIANO MEDICAL SCIENCES S.R.L.
Inventors
PICCONI, Pietro
MIRIZZI, Danilo
BUFFA, Laura
ORRENIUS, Sten Christian
ASA, Daniela Silvia
Priority Data
24175771.5
14.05.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 5192 | |
| EPO | Filing, Examination | 19844 | |
| Japan | Filing | 589 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 29410 |
Total:
55,609
Abstract[English]
The present invention relates to substituted quinoline derivatives of formula (I) as inhibitors of the activity of RAD51 for the treatment of cancer, cell proliferative disorders or immune disorders.[French]
La présente invention concerne des dérivés de quinoléine substitués de formule (I) utilisés en tant qu'inhibiteurs de l'activité de RAD51 pour le traitement du cancer, de troubles de prolifération cellulaire ou de troubles immunitaires.